SHA:600535 Revenue

Tasly Pharmaceutical Group had revenue of 2.16B CNY in the quarter ending March 31, 2026, with 5.35% growth. This brings the company's revenue in the last twelve months to 8.35B, down -1.86% year-over-year. In the year 2025, Tasly Pharmaceutical Group had annual revenue of 8.24B, down -3.08%.

Revenue (ttm)

8.35B

Revenue Growth

-1.86%

P/S Ratio

2.68

Revenue / Employee

790.15K

Employees

10,563

Market Cap

22.38B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	8.24B	-261.66M	-3.08%
Dec 31, 2024	8.50B	-175.87M	-2.03%
Dec 31, 2023	8.67B	36.58M	0.42%
Dec 31, 2022	8.64B	685.47M	8.62%
Dec 31, 2021	7.95B	-5.62B	-41.43%
Dec 31, 2020	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2018	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2017	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2016	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Apeloa Pharmaceutical Co.,Ltd	9.50B
Zhejiang Huahai Pharmaceutical	8.71B
Jiangsu Nhwa Pharmaceutical Co., LTD	6.01B
Hubei Jumpcan Pharmaceutical	5.90B
Kangmei Pharmaceutical	5.25B
Chengdu Kanghong Pharmaceutical Group	4.43B
Betta Pharmaceuticals	3.73B
Jilin Aodong Pharmaceutical Group	2.34B

Revenue Rankings